Lacy Stark
Nurse Practitioner · Fort Worth, TXNPI 1922510205
Payments from drug & device makers
Across 419 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biogen$380
- Novartis$356
- Pfizer$343
- SK Life Science, Inc.$340
- UCB, Inc.$279
- plus $4K from 51 others
What the payments were for
- Food & beverage$7,30099%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,346 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 16 | $149,456 |
| IngrezzaValbenazine Tosylate | 12 | $97,179 |
| RytaryCarbidopa/Levodopa | 39 | $61,451 |
| Aimovig AutoinjectorErenumab-Aooe | 53 | $47,540 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 11 | $44,700 |
| Nurtec OdtRimegepant Sulfate | 33 | $37,316 |
| QuliptaAtogepant | 13 | $27,124 |
| UbrelvyUbrogepant | 12 | $21,399 |
| XcopriCenobamate | 11 | $16,475 |
| Gabapentin | 323 | $8,145 |
| Duloxetine Hcl | 233 | $6,748 |
| Rivastigmine | 38 | $4,867 |
| Memantine Hcl | 136 | $4,449 |
| Levetiracetam | 133 | $4,428 |
| Primidone | 106 | $4,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $81 | $97,17912 claims |
| Amneal Pharmaceuticals LLCRytary | $261 | $61,45139 claims |
| AbbVieQulipta, Ubrelvy | $1,982 | $48,52425 claims |
| PfizerNurtec Odt | $343 | $37,31633 claims |
| SK Life Science, Inc.Xcopri | $340 | $16,47511 claims |
| Almatica Pharma LLCSertraline Hcl | $29 | $2,338226 claims |
| Upsher-smith Laboratories LLCTopiramate | $37 | $94779 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Fort Worth
- Deborah StapelFort Worth$44K
- Jessica RothFort Worth$15K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.